Dr. Hall on Multigene Target Panels for Genetic Weaknesses

Michael J. Hall, MD
Published: Thursday, Jul 02, 2015



Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.

Multigene panels have been developed for practitioners to evaluate tumors for genetic and genomic weaknesses, Hall explains. However, the fact that detected mutations within tumors are reflective of potential germline variations is understudied. This should be a significant area of research, Hall adds, because patients may be at risk for other cancers or may be unaware of risks associated with their family history.

In a collaboration between Fox Chase Cancer Center and Foundation Medicine, a multigene target panel tested approximately 15,000 tumors. Researchers examined a subset of the tested genes that were known for hereditary cancer risk to determine how many of them were pathogenic.
 


Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.

Multigene panels have been developed for practitioners to evaluate tumors for genetic and genomic weaknesses, Hall explains. However, the fact that detected mutations within tumors are reflective of potential germline variations is understudied. This should be a significant area of research, Hall adds, because patients may be at risk for other cancers or may be unaware of risks associated with their family history.

In a collaboration between Fox Chase Cancer Center and Foundation Medicine, a multigene target panel tested approximately 15,000 tumors. Researchers examined a subset of the tested genes that were known for hereditary cancer risk to determine how many of them were pathogenic.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x